论文部分内容阅读
引言 血液透析患者对乙肝病毒(HBV)有高度危险的感染性,一经感染他们就易成为HBV的慢性携带者。很可能是由于体液与细胞免疫反应受损所致,这些患者不仅对乙肝病毒免疫反应降低,而且对乙肝疫苗的应答也降低。在注射3针5μg剂量的巴氏疫苗(巴斯德研究所生产)后发现共抗-HBs应答只有60％到62％。虽然以前曾报导注射3针40μg的Merck疫苗后有89％的抗-HBs应答率,在大量血液透析患者中更广泛的研究表明其应答率仅有65％(C.E.Stev
Introduction Hemodialysis patients are highly dangerous to hepatitis B virus (HBV) and, once infected, are predisposed to becoming chronic carriers of HBV. Probably due to impaired humoral and cellular immune responses, these patients have not only a reduced immune response to hepatitis B virus but also a lower response to hepatitis B vaccine. A total of 60% to 62% of the co-anti-HBs response was found after injection of a 3-dose 5 μg dose of the pasteurized vaccine (produced by the Pasteur Institute). Although 89% of anti-HBs responses have been reported previously in the injection of the 3-dose 40 μg Merck vaccine, a broader study in a large number of hemodialysis patients showed a response rate of only 65% (C.E. Stev